Validity Testing Information Part I

Laboratory Name:
Address:

Responsible Person:

Stephen C. Erfurth, Ph.D

_ (Printed Name)

I certify that the answers and information provided are true and correct as of this date. Any false, fictitious, or fraudulent answers or ir formation provided may violate Federal Law and could subject me to prosecution, mor etary penalties, or both (Sec 18 U.S.C. 1001; 31 U.S.C. 3801-812).

Signature, Responsible Person

/0-03-00 Date

Stephen C. Erfurth, Ph.D

Printed Name, Responsible Person



OREGON MEDICAL LABORATORIES - TOXICOLOGY

Facsimile Cover Letter

Flease deliver the following pages to:		
Hame: Research Triangle Institute	FAX No.	(919) 591- 7092
Dept.:	Phone:	
From: Dr. Erfurth	Fax:	1-541-341-8095
We are transmitting pages including this cover_	estar.	
Date: 10/3/60 Time: 1024		

FOR ASSISTANCE - Call 1-800-826-3616, ext. 8112

This faceinale transmission (and any attached documents) is for the use of the individual used after a first contain information that is privileged, confidential and exempt from disciousive under pertinent law. If the reader or receiver of this FAX is not the interior receipt to agent responsible for receipt and delivery to the intended recipient) you are bereby notified that any distribution or copying of this communication is strictly problemed. If you have received this document in error, please notify as immediately by telephone to arrange for return of this communication (without copying).

6946 1/94

OREGON MEDICAL LABORATORIES - TOXICOLOGY

Facsimile Cover Letter

Please deliver the following pages to:		
Name: FRANK WALLIS	FAX No: (919) 541-7042	
Dept.: RT1	Fhone:	
From: Corport BEARDSLEY	Fax: 1-541-341-8095	
We are transmitting pages including this cover letter.		
Date: 10/18/00 Time: 0746		
FOR ASSISTANCE - Call (-\$	\$137 30-826-3616, ext. -8112	

This firstimile transmission (and any stached documents) is for the use of the individual listed shore, and may contain information that is privileged, confidential and exempt from disclosure under pertinent law. If the reader or receiver of this FAX is not the introduced responsible for receipt and delivery to the introduced responsible on receipt and delivery to the introduced responsible that any distribution or copying of this communication is strictly promitived. If you have received this document in error, please notify us immediately by telephone to arrange for return of this communication (without copying).

6946 1794

Validity Testing Information Part II

Conduct an audit of all DOT regulated specimens from the date your laboratory started validity testing. Summarize your findings in an Excel spread sheet in both hard copy and electronic format. Provide the following information in a separate column of the spreadsheet/audit for each DOT regulated specimen that was reported either adulterated or substituted:

- Specimen ID number
- Laboratory Accession Number
- Date of receipt
- Date reported
- Reported result (i.e., adulterated or substituted)
- Quantitative test result (e.g., actual creatinine concentration and specific gravity reading; actual pH reading; adulterant identity and its concentration if applicable)

Note: Retain a copy of this information to ensure that you would be able to retrieve additional data.

I certify that the answers and information provided are true and correct as of this date. Any false, fictitious, or fraudulent answers or information provided may violate Federal Law and could subject me to prosecution, monetary penalties, or both (Sec 18 U.S.C. 1001; 31 U.S.C. 3801-812).

Signature, Responsible Person

Stephen C. Erfurth, Ph.D

Printed Name, Responsible Person

Spec ID# Accession Receipt Reported Reported Result

Oregon Medical Laboratories, Eugene, ÖR #0306

Creatinine Nitrite Sp Grav pH

Page 1

RESEARCH TRIANGLE INSTITUTE




National Laboratory Certification Program

December 13, 2000

0306 Dr. Stephen C. Erfurth Oregon Medical Laboratories 722 East 11th Avenue Eugene, OR 97401


Dear Dr. Eurfurth:

The enclosed critique was developed from the inspection report associated with the November 15, 2000 specimen validity testing inspection of your laboratory under the National Laboratory Certification Program (NLCP). The laboratory's procedures were not in compliance with program guidance issued in Program Document 035 (September 28, 1998) and Program Document 037 (July 28, 1999). The laboratory must submit information to address the following issues raised:





Dr. Erfurth December 13, 2000 Page 2 of 2



The laboratory must submit, within 30 calendar days of receipt of this letter, documentation to demonstrate that corrective actions have been implemented to address the issues listed in this correspondence. The laboratory must also review the enclosed critique and take all necessary corrective actions. In responding to these issues, please organize the material in your document in accordance with the sections and item numbers as listed in this correspondence. All corrective actions must be implemented within 30 days receipt of this correspondence and will be reviewed at the next inspection. Failure to comply may result in the laboratory's suspension to perform specimen validity testing on federally regulated specimens.

If you have any questions or if we can be of further assistance, please call me at (919) 541-7265 or Dr. Michael Baylor at (919) 541-7043.

Sincerely,

Deborah J. Denson

NLCP Technical Analyst

Deborah J Denson

Enclosure

cc. Projec

NATIONAL LABORATORY CERTIFICATION PROGRAM

Document Review and Critique

Laboratory I.D. Number: **Q306**

Document No. Final

Laboratory:

Oregon Medical Laboratories

Location:

Eugene, OR

Document Reviewed:

[XX] Specimen Validity Testing Inspection Report

Date: 15 November 2000

A review of the National Laboratory Certification Program (NLCP) consensus inspection report has been completed. Issues identified during the inspection are described on the following pages. Evidence that appropriate remedial action has been taken is required for continued certification.

The following comments were noted, and appear in the same order as the corresponding questions in the Laboratory Inspection Report:

Section E. Standard Operating Procedures - Procedures Manual

Section F. Chain-of-Custody, Accessioning, and Security

Section G. Quality Control and Quality Assurance


Section I. Specimen Validity Tests

Section K. Records Audit

11. The following issues were identified:

Section L. Certification and Reporting





722 E. 11th Avenue Post Office Box 972 Eugene, Oregon 97440-0972

January 12, 2001

541+687+2134 1+800+826+3616


Pathologists
Mathews B, Fish, M.D.
David A. Rutz, M.D.
David S. Meyers, M.D.
Brent D. Kehn, M.D.
Michael J. Hahn, M.D.
L. Samuel Vickers, M.D.
Curtis R. Liu, M.D.
Jeffrey A. Houck, M.D.
Sandra L. Moran, M.D.
Kathleen C. Masterson, M.D.
Clinical Chemist
Stephen C, Erfurth, Ph.D.
Clinical Microbiologist
Anthony H. Gonzalez, Ph.D.

Deborah J. Denson National Laboratory Certification Program Research Triangle Institute P.O. Box 12194 3040 Cornwallis Road Research Triangle Park, NC 27709

RE: Corrective actions, SVT Inspection of laboratory #0306

Dear Ms. Denson:

We received you letter dated December 13, 2000 on December 14, 2000 regarding our specimen validity testing (SVT) inspection last November 15th. The laboratory procedures listed in your correspondence have been address and are summarized here:



Please telephone 1-541-687-2134 to contact either Grant Beardsley (x.8137) or myself (x.8092) if we can provide any additional information or clarification relative to this document.

Sincerely,

Stephen C. Erfurth, Ph.D.

Responsible Person

Enclosures:

Attachments as Exhibits 1 - 4

RESEARCH TRIANGLE INSTITUTE



National Laboratory Certification Program

February 6, 2001

0306 Dr. Stephen C. Erfurth Oregon Medical Laboratories 722 East 11th Avenue Eugene, OR 97401

Dear Dr. Eurfurth:

We have reviewed the material provided in your correspondence of January 12, 2001 submitted in response to issues raised during the November 15, 2000 specimen validity testing inspection of your laboratory as outlined in our correspondence of December 13, 2000. The information submitted by the laboratory appears to demonstrate that corrective actions have been taken to address the issues raised. The following is a review of the material submitted:

Based upon our review of the material submitted, it appears that the laboratory is taking steps to ensure that its specimen validity testing procedures are in compliance with program guidance. All corrective actions must be implemented within 30 days of the



Dr. Eurfurth February 6, 2001 Page 2 of 2

receipt of this correspondence and will be reviewed during the next inspection. Failure to comply may result in the laboratory's suspension to perform specimen validity testing on federally regulated specimens.

If you have any questions or if we can be of further assistance, please call me at (919) 541-7265 or Dr. Michael R. Baylor at (919) 541-7043.

Sincerely,

Deborah J. Denson NLCP Technical Analyst

cc: Project Files/SVT306